Clinical Spectrum of SCN5A Mutations: Long QT Syndrome, Brugada Syndrome, and Cardiomyopathy

Authors, Journal, Affiliations, Type, DOI

• Arthur A.M. Wilde MD PhD; Ahmad S. Amin MD PhD
• Heart Centre, Academic Medical Center, University of Amsterdam, the Netherlands; Columbia University Irving Medical Centre, New York
• JACC: Clinical Electrophysiology, Vol 4 No 5, May 2018, pp 569–579
• State-of-the-art review (CME/MOC designated)
• DOI: https://doi.org/10.1016/j.jacep.2018.03.006

Overview

This landmark state-of-the-art review by two leading SCN5A experts covers the full clinical spectrum of SCN5A mutations — from the pure electrical disorder LQT3 (gain-of-function, increased late INa/window current) through Brugada syndrome (loss-of-function, now re-classified as a possible partial cardiomyopathy with RVOT structural changes), to dilated cardiomyopathy (mixed mechanisms). Additional sections cover Lev-Lenègre syndrome, sick sinus syndrome, familial AF, multifocal ectopic Purkinje-related premature complexes (MEPPC), and overlap syndromes. The paper establishes the principle that clinical phenotype is determined by which gating property is affected and in which direction, enabling mutation-specific management strategies.

Keywords

SCN5A, Nav1.5, Long QT syndrome, Brugada syndrome, dilated cardiomyopathy, gain-of-function, loss-of-function, late sodium current, overlap syndrome, cardiac sodium channel

Key Takeaways

SCN5A and the Cardiac Sodium Channel

• SCN5A encodes Nav1.5, the pore-forming α-subunit of the cardiac sodium channel, responsible for phase 0 depolarization of atrial, ventricular, and Purkinje myocytes. SCN5A has 28 exons and is highly conserved.
• Nav1.5 is preferentially expressed at the intercalated disc where it interacts with β-subunits, desmosomal proteins, gap junction proteins, and intracellular scaffolding proteins — mutations in any of these interacting proteins can produce SCN5A-like phenotypes.
• Nav1.5 structure: 4 homologous domains (DI–DIV) × 6 transmembrane segments each; P-loops between S5–S6 form the ion-conducting pore; S4 voltage sensor drives activation; DIII–DIV intracellular linker (IFM motif) mediates fast inactivation; late current (INaL) and window current arise from a small fraction (<1%) of channels that fail to inactivate or re-open during repolarization.
• The final phenotypic outcome depends on which gating property is altered and in which direction.

Long QT Syndrome (LQT3)

• LQT3 accounts for 5–10% of genotype-positive LQTS (behind KCNQ1/LQT1 ~35% and KCNH2/LQT2 ~30%).
• Mechanism: SCN5A gain-of-function → pathological increase in INaL or window current (or both) → prolonged plateau phase → delayed repolarization. These residual currents amplify at slow heart rates (longer plateau), explaining the bradycardia-dependent QT prolongation and normalization at fast heart rates.
• Clinical hallmarks distinguishing LQT3 from LQT1/LQT2:
  • Marked resting bradycardia; QT prolongs more at slow HR, normalizes at fast HR
  • Arrhythmic events occur more often at rest/sleep (vs. exercise in LQT1, auditory stimuli in LQT2)
  • First cardiac event is more likely to be fatal
  • Onset tends to be after puberty (vs. childhood in LQT1)
• Downstream consequences of persistent Na⁺ influx: Intracellular Na⁺ overload → reverse-mode NCX activation → intracellular Ca²⁺ overload → impaired contraction, relaxation, and increased oxygen consumption — a pathway also relevant in heart failure.
• Interacting protein variants: Caveolin-3, β4-subunit, α1-syntrophin mutations linked to increased INa/INaL → LQT3-like phenotype.

LQT3 Management

• Beta-blockers: Initially considered ineffective or harmful in LQT3; later studies demonstrated clear benefit — beta-blockers are now recommended.
• Mexiletine (INaL blocker): Shortens QT interval acutely. Long-term registry (n=34, median follow-up 36 months) demonstrated significant reduction in all arrhythmic events. Flecainide and ranolazine also shorten QT in short-term studies.
• ICD: Indicated in symptomatic patients with QTc >500 ms; also indicated after resuscitated VF or haemodynamically compromised VT.
• Risk stratification: Primarily based on symptomatic status and QTc duration at baseline. Asymptomatic with QTc >500 ms = high risk warranting prophylactic ICD consideration.

Brugada Syndrome (BrS)

• Diagnosis: Only type 1 ECG (J-point >2 mm in ≥1 precordial lead) is diagnostic; drug provocation (e.g., ajmaline) required if not spontaneous — additional diagnostic criteria must also be met.
• Genetics: SCN5A is the only gene significantly over-represented in BrS patients vs. controls; other >20 genes have variants also found in healthy controls. Genome-wide association studies confirm oligogenic architecture with SCN5A as the dominant factor. Phenotype-positive/genotype-negative family members of SCN5A-positive families exist — supporting additional penetrance modifiers.
• Mechanism: Loss-of-function — decreased Nav1.5 surface expression, non-functional channels, or gating changes reducing INa (delayed activation, accelerated inactivation). The mechanism for ST elevation is debated (multiple competing hypotheses).
• BrS as partial cardiomyopathy: Growing evidence of structural RVOT abnormalities on CMR (enlarged ventricular volumes, structural changes). BrS is increasingly considered part of a cardiomyopathy spectrum rather than a pure electrical disorder.
• Conduction defects: BrS is frequently associated with conduction delays at all cardiac levels, especially with SCN5A mutations; increased supraventricular arrhythmia risk.
• External arrhythmia triggers: Fever (most important), and a long list of sodium channel-blocking drugs.

BrS Management

• ICD: Mandatory for documented life-threatening arrhythmias (Class I). For asymptomatic spontaneous type 1 ECG — risk is debated; most clinical parameters lack strong consensus.
• Drug-induced type 1 ECG alone: Associated with benign prognosis; no invasive approach warranted.
• EP testing: Pooled analysis supports a small predictive role for non-aggressive stimulation (double extrastimuli from RV apex only).
• Quinidine: Effective pharmacological therapy for chronic management (Ito blocker); good results documented in observational studies. No randomized long-term trial.
• Isoproterenol IV: First-line for arrhythmic storm.
• Epicardial RVOT catheter ablation: Promising results for ECG normalization and arrhythmia elimination; should be approached from the epicardial side; reserved for experienced centres.
• Lifestyle: Exercise generally not restricted (though ST changes may worsen during exercise in some); fever requires antipyretics + ECG monitoring; avoid drugs on brugadadrugs.org; limit alcohol.

Dilated Cardiomyopathy (DCM)

• Prevalence: IDCM ~1:2,500; familial forms 30–50% of IDCM.
• SCN5A in DCM: First linked in 2004 (D1275N mutation in a 5-generation family). >20 SCN5A mutations now linked to DCM; >90% are missense variants.
• Age-dependent penetrance: Most SCN5A-DCM presents with increasing age.
• Conduction defects precede DCM by 15–20 years: First/second-degree AV block, LBBB, RBBB are nearly universal — a critical clue to SCN5A involvement in unexplained DCM.
• Arrhythmias in >90% of SCN5A-DCM: AF, sick sinus syndrome, PVCs, VT.
• Molecular mechanisms of SCN5A mutations in DCM:
  • Half cause loss-of-function (reduced membrane expression, adverse gating changes)
  • One-third cause gain-of-function (increased window current)
  • Some cause both; S4-segment missense mutations create an aberrant pore allowing cation leak
• Three hypotheses for how SCN5A mutations cause ventricular dilatation:
  1. Direct: Nav1.5 interacts with cytoskeletal and intercalated disc proteins; mutations disrupt these interactions → structural deformation; alternatively, cation leakage or Na⁺/Ca²⁺ overload → intracellular acidification or Ca²⁺ overload → impaired contraction
  2. Conduction-defect-mediated (indirect): Conduction defects → dyssynchrony → progressive DCM; supported by timing data (conduction defects precede DCM 15–20 years) and mouse models (90% SCN5A knockdown mice develop DCM features)
  3. Arrhythmia-mediated: Long-lasting arrhythmias → tachycardia-induced CMP; supported by cases of reversible DCM after arrhythmia suppression (hydroquinidine, flecainide, amiodarone) — particularly in MEPPC (R222Q)

SCN5A-DCM Management

• Exclude common DCM causes first; presence of AV conduction defects + AF/SSS suggests SCN5A involvement → family screening.
• Genetic testing indicated for IDCM with frequent ventricular ectopy or severe conduction defects.
• When SCN5A confirmed: Standard HF therapy; avoid sodium channel blockers (risk of worsening conduction); amiodarone for arrhythmias.
• Paradoxical sodium channel blocker use: In selected cases with frequent PVC burden, without significant conduction defects or CMR fibrosis → hydroquinidine or flecainide may be considered (preferably after LV function normalisation with HF therapy/amiodarone).

Other SCN5A Diseases

• Lev-Lenègre syndrome: Progressive conduction system fibrosis → P-wave/PR/QRS prolongation → bundle branch blocks → complete AVB at advanced age. Loss-of-function SCN5A implicated.
• Sick sinus syndrome (SSS): Familial autosomal dominant SSS presents at younger age. SCN5A loss-of-function is the most commonly implicated gene. Atrial standstill also reported, sometimes with connexin-43 polymorphism.
• Atrial fibrillation: Both LOF (intra-atrial conduction slowing) and GOF (EAD/DAD-triggered AF via prolonged APD or enhanced Na⁺ entry) mechanisms implicated in familial AF.
• MEPPC (Multifocal Ectopic Premature Purkinje-related Complexes): R222Q SCN5A gain-of-function → increased window current → premature action potentials in Purkinje cells → high-burden narrow complex polymorphic PVCs; reversible DCM in some patients; similar phenotype also with R222P and I141V variants.

SCN5A Overlap Syndromes

• First described: 1795insD mutation in a Dutch multigenerational family — simultaneous LOF features (SSS, bradycardia, conduction disease, BrS) and GOF features (LQT3).
• Mechanistic explanation: Phase 0 loss-of-function (reduced peak INa) coexists with phases 2–3 gain-of-function (increased INaL/window current) — the biophysical effects segregate at different phases of the action potential.
• Phenotypic modifiers: Male sex → BrS predominance; female sex → conduction disorders; advancing age → worsening conduction; SCN5A SNPs (genetic modifiers) independently influence phenotype.
• The most common overlap combination clinically is BrS + cardiac conduction defects (SCN5A-based BrS characteristically shows prolonged conduction intervals throughout the heart).

Limitations of the Document

• 2018 publication — epicardial BrS ablation data, EP testing evidence, and risk stratification tools have been updated since
• Review-level evidence for most management recommendations; LQT3 mexiletine data from a single registry of only 34 patients (short follow-up)
• Mechanistic understanding of SCN5A-DCM remains incomplete — the three hypotheses are not mutually exclusive and their relative contributions are unknown
• Drug provocation data and BrS genetic architecture discussed before the 2025 EHRA pharmacological provocation consensus
• Overlap syndrome section primarily based on one Dutch founder mutation (1795insD) — generalizability to other overlap mutations uncertain

Key Concepts Mentioned

• concepts/Ion-Channel-Mutations — GOF vs LOF as the determinant of SCN5A phenotype
• concepts/Cardiac-Action-Potential — INaL, window current, phase 0, plateau
• concepts/Cardiac-Repolarization — QT prolongation, late sodium current
• concepts/Electrical-Remodeling — downstream consequences of Na⁺/Ca²⁺ overload
• concepts/VA-Risk-Stratification-DCM — SCN5A-DCM risk features

Key Entities Mentioned

• entities/SCN5A — central subject of this review
• entities/Long-QT-Syndrome — LQT3 phenotype, mechanistic basis, management
• entities/Brugada-Syndrome — LOF mechanism, structural RVOT findings, management
• entities/DCM — SCN5A-linked DCM, three pathomechanisms, management

Wiki Pages Updated

• wiki/sources/scn5a-jaccep-2018.md — created
• wiki/sourceindex.md — updated
• wiki/wikiindex.md — updated
• wiki/entities/SCN5A.md — updated
• wiki/entities/Long-QT-Syndrome.md — updated
• wiki/entities/Brugada-Syndrome.md — updated
• wiki/entities/DCM.md — updated